CD44 and carcinoma: Scientists were able to identify a minor fraction (0.2–0.8%) of carcinoma cells, co-expressing CD24, CD44 and epithelial-specific antigen (ESA) and featuring high tumorigenicity, self-renewal capabilities and the ability to produce phenotypically diverse cancer cells [16].